BACKGROUNDTriple-detrimental breast cancer (TNBC) is extremely intense with an increased metastatic incidence in comparison with other breast cancer subtypes. On the other hand, as a result of absence of clinically trustworthy biomarkers and targeted therapy in TNBC, outcomes are suboptimal. That